Proteomics

Dataset Information

0

Mapping naturally presented T-cell antigens in medulloblastoma based on integrative multi-omics


ABSTRACT: Medulloblastoma is the most frequent malignant primary brain tumor in children. Despite recent advances in integrated genomics, the prognosis in children with high-risk medulloblastoma remains devastating, and new tumor-specific therapeutic approaches are needed. Here, we present an atlas of naturally presented T-cell antigens in medulloblastoma. We mapped the human leukocyte antigen (HLA)-presented peptidomes of 28 tumors and performed comparative immunopeptidome profiling against an in-house benign database. Medulloblastoma proved to be a rich source of novel tumor-associated antigens, naturally presented on HLA class I and II molecules. Remarkably, most tumor-associated peptides and proteins were subgroup-specific, whereas shared presentation among all subgroups of medulloblastoma (WNT, SHH, Group 3 and Group 4) was rare. Functional testing of top-ranking novel candidate antigens demonstrated the induction of peptide-specific T-cell responses, supporting their potential for T-cell immunotherapy. This study is an in-depth mapping of naturally presented T-cell antigens in medulloblastoma. Integration of immunopeptidomics, transcriptomics, and epigenetic data led to the identification of a large set of actionable targets that can be further used for the translation into the clinical setting by facilitating the informed design of immunotherapeutic approaches to children with medulloblastoma.

INSTRUMENT(S): Orbitrap Fusion Lumos

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain

DISEASE(S): Brain Cancer

SUBMITTER: Jonas Scheid  

LAB HEAD: Marian Christoph

PROVIDER: PXD043770 | Pride | 2024-08-24

REPOSITORIES: Pride

Similar Datasets

2018-12-11 | PXD010450 | Pride
2022-07-19 | PXD035324 | Pride
2023-02-27 | PXD033383 | Pride
2024-08-24 | GSE238195 | GEO
2024-08-24 | GSE250586 | GEO
2023-08-23 | PXD038691 | Pride
2023-02-20 | PXD036811 | Pride
2023-07-05 | PXD041804 | Pride
2022-05-31 | PXD033935 | Pride
2021-04-16 | PXD019643 | Pride